Literature DB >> 3277684

Mortality in rheumatoid arthritis.

D P Symmons.   

Abstract

Rheumatoid arthritis (RA) is often regarded as a non-fatal disease. Yet patients with RA have a substantially reduced life expectancy. Increased mortality in RA is associated with a long disease duration, with severe disabling arthritis and with systemic involvement. Patients with chronic RA are particularly at risk of death from bacterial infection and renal disease. The influence of treatment on mortality remains unclear. In patients with mild RA, the treatments may be more toxic than the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277684

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

Review 1.  Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis?

Authors:  R M Lowenthal; S R Graham
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

Review 2.  What should we hope to achieve when treating rheumatoid arthritis?

Authors:  D L Scott; T D Spector; T Pullar; B McConkey
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

Review 3.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

4.  Mortality in rheumatoid arthritis patients with disease onset in the 1980s.

Authors:  E Lindqvist; K Eberhardt
Journal:  Ann Rheum Dis       Date:  1999-01       Impact factor: 19.103

5.  No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.

Authors:  E J Kroot; M A van Leeuwen; M H van Rijswijk; M L Prevoo; M A Van 't Hof; L B van De Putte; P L van Riel
Journal:  Ann Rheum Dis       Date:  2000-12       Impact factor: 19.103

6.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

7.  Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Authors:  R Roubenoff; R A Roubenoff; J G Cannon; J J Kehayias; H Zhuang; B Dawson-Hughes; C A Dinarello; I H Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Arthritis and mortality in the epidemiological follow-up to the National Health and Nutrition Examination Survey I.

Authors:  J P Leigh; J F Fries
Journal:  Bull N Y Acad Med       Date:  1994

9.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.